Other

Precision Medicine in Early Oncology Trials: Biomarkers as Strategic Drivers

Pharmaceutical Technology

Biomarkers are revolutionizing oncology drug development, driving modern precision medicine approaches, targeted clinical trial recruitment strategies, and critical decision-making.

Related Stories

ASCO ’26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer

ASCO26: Symptom-tracking app helps advanced cancer patients

All eyes on Revolution, bispecific antibodies and more at ASCO26

You May Have Missed

Alzecure enters collaboration and with Lilly for Alzheimer’s project

ADA: AstraZeneca hands Structure a win with ‘relatively underwhelming’ GLP-1 pill data

GSK pays $10.6B for cancer biotech Nuvalent in industry’s second-biggest buy of the year

ADA: Lilly bests Novo again, takes GLP-1 pill Foundayo to FDA for diabetes approval